Major Femoral Bleeding Complications After Percutaneous Coronary Intervention Incidence, Predictors, and Impact on Long-Term Survival Among 17,901 Patients Treated at the Mayo Clinic From 1994 to 2005

被引:209
作者
Doyle, Brendan J. [1 ]
Ting, Henry H. [1 ]
Bell, Malcolm R. [1 ]
Lennon, Ryan J. [1 ]
Mathew, Verghese [1 ]
Singh, Mandeep [1 ]
Holmes, David R. [1 ]
Rihal, Charanjit S. [1 ]
机构
[1] Mayo Clin, Cardiac Catheterizat Lab, Coll Med, Dept Internal Med,Div Cardiovasc Dis, Rochester, MN 55905 USA
关键词
D O I
10.1016/j.jcin.2007.12.006
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objectives The purpose of this study was to evaluate secular trends and factors associated with major femoral bleeding after percutaneous coronary intervention (PCI) in routine clinical practice during the past decade and to assess the impact of these complications on outcomes including mortality. Background Significant changes in patient demographic data, adjunctive pharmacotherapy, and access site management have occurred during the coronary stent era. Trends in major vascular complications after PCI during this time have not been well characterized. Methods Consecutive patients who underwent transfemoral PCI from 1994 to 2005 at the Mayo Clinic (n = 17,901) were studied. Patients were divided into 3 groups: Group 1 (1994 to 1995, n = 2,441); Group 2 (1996 to 1999, n = 6,207); and Group 3 (2000 to 2005, n = 9,253). Results The incidence of major femoral bleeding complications decreased (from 8.4% to 5.3% to 3.5%; p < 0.001). Reductions in sheath size, intensity and duration of anticoagulation with heparin, and procedure time were observed (p < 0.001), and multivariate analysis confirmed each as an independent predictor of complications (p < 0.001). Adverse outcomes of major femoral bleeding included prolonged hospital stay (mean 4.5 vs. 2.7 days; p < 0.0001) and increased requirement for blood transfusion (39% vs. 4.7%; p < 0.0001). Major femoral bleeding and blood transfusion were both associated with decreased long-term survival, driven by a significant increase in 30-day mortality (p < 0.001 for both). Conclusions We noted a marked decline in the incidence of major femoral bleeding after PCI over the past decade. Mortality associated with these bleeding complications and with blood transfusion remains a significant issue. (J Am Coll Cardiol Intv 2008;1:202-9) (C) 2008 by the American College of Cardiology Foundation
引用
收藏
页码:202 / 209
页数:8
相关论文
共 25 条
[1]   Safety of abciximab in patients with chronic renal insufficiency who are undergoing percutaneous coronary interventions [J].
Best, PJM ;
Lennon, R ;
Gersh, BJ ;
Ting, HH ;
Rihal, CS ;
Bell, MR ;
Herzog, CA ;
Holmes, DR ;
Berger, PB .
AMERICAN HEART JOURNAL, 2003, 146 (02) :345-350
[2]   Vascular access site complications after percutaneous coronary intervention with abciximab in the evaluation of c7E3 for the prevention of ischemic complications (EPIC) trial [J].
Blankenship, JC ;
Hellkamp, AS ;
Aguirre, FV ;
Demko, SL ;
Topol, EJ ;
Califf, RM .
AMERICAN JOURNAL OF CARDIOLOGY, 1998, 81 (01) :36-40
[3]   FEMORAL-ARTERY CATHETERIZATION COMPLICATIONS - A STUDY OF 503 CONSECUTIVE PATIENTS [J].
BOGART, DB ;
BOGART, MA ;
MILLER, JT ;
FARRAR, MW ;
BARR, WK ;
MONTGOMERY, MA .
CATHETERIZATION AND CARDIOVASCULAR DIAGNOSIS, 1995, 34 (01) :8-13
[4]   Infectious and ischemic complications from percutaneous closure devices used after vascular access [J].
Boston, US ;
Panneton, JM ;
Hofer, JM ;
Sabater, EA ;
Caplice, N ;
Rowland, CM ;
Noel, AA ;
Bower, TC ;
Cherry, KJ ;
Gloviczki, P .
ANNALS OF VASCULAR SURGERY, 2003, 17 (01) :66-71
[5]  
Carey D, 2001, CATHETER CARDIO INTE, V52, P3, DOI 10.1002/1522-726X(200101)52:1<3::AID-CCD1002>3.0.CO
[6]  
2-G
[7]  
Cote AV, 2001, MAYO CLIN PROC, V76, P890
[8]   Correlates and outcomes of retroperitoneal hemorrhage complicating percutaneous coronary intervention [J].
Ellis, SG ;
Bhatt, D ;
Kapadia, S ;
Lee, D ;
Yen, M ;
Whitlow, PL .
CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS, 2006, 67 (04) :541-545
[9]   Risk factors for the development of retroperitoneal hematoma after percutaneous coronary intervention in the era of glycoprotein IIb/IIIa inhibitors and vascular closure devices [J].
Farouque, HMO ;
Tremmel, JA ;
Shabari, FR ;
Aggarwal, M ;
Fearon, WF ;
Ng, MKC ;
Rezaee, M ;
Yeung, AC ;
Lee, DP .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2005, 45 (03) :363-368
[10]   MULTICENTER INVESTIGATION OF CORONARY STENTING TO TREAT ACUTE OR THREATENED CLOSURE AFTER PERCUTANEOUS TRANSLUMINAL CORONARY ANGIOPLASTY - CLINICAL AND ANGIOGRAPHIC OUTCOMES [J].
GEORGE, BS ;
VOORHEES, WD ;
ROUBIN, GS ;
FEARNOT, NE ;
PINKERTON, CA ;
RAIZNER, AE ;
KING, SB ;
HOLMES, DR ;
TOPOL, EJ ;
KEREIAKES, DJ ;
HARTZLER, GO .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1993, 22 (01) :135-143